A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/Day) as Treatment for Adults With Excessive Sleepiness Associated With Narcolepsy.
Latest Information Update: 22 Jul 2013
At a glance
- Drugs Armodafinil (Primary)
- Indications Narcolepsy
- Focus Registrational; Therapeutic Use
- Sponsors Cephalon
Most Recent Events
- 01 Feb 2010 New trial record